Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00120120 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Painful Lumbar Radiculopathy
A Phase 2 study, sponsored by Celgene Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 181
- Enrollment target
NCT00120120 is a Phase 2 study that has completed, run by Celgene Corporation. The registered enrollment target is 181 participants.
The verdict
NCT00120120, a Phase 2 study, has completed, sponsored by Celgene Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 181 participants
- Enrollment target
Study Summary
The purpose of this multicenter, double-blind, placebo-controlled study is to evaluate the efficacy and safety of lenalidomide in the treatment of painful lumbar radiculopathy.
Interventions
- DRUG Lenalidomide (CC-5013)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 181 participants |
| Start Date | 2005-01 |
| Est. Completion | 2007-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00120120
The ClinicalTrials.gov registry entry for NCT00120120 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 181 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene Corporation, which has 40 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lenalidomide (CC-5013) is the first listed.
NCT00120120 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00120120 about?
NCT00120120 is a clinical study titled "Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Painful Lumbar Radiculopathy". The purpose of this multicenter, double-blind, placebo-controlled study is to evaluate the efficacy and safety of lenalidomide in the treatment of painful lumbar radiculopathy.
What is the current status of trial NCT00120120?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 181 participants. The study started on 2005-01. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00120120?
The interventions under investigation include: Lenalidomide (CC-5013) (DRUG).
Who is sponsoring clinical trial NCT00120120?
This trial is sponsored by Celgene Corporation, which has 40 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.